A Comparative Analysis of Patients with Progressive Vitiligo Treated with Tofacitinib versus Oral Mini-Pulse Steroid Therapy
International Journal of Pharmaceutical Quality Assurance · 30.10.2026 · 17 (10)
DOI: 10.25258/ijpqa.17.10.21 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Pharmaceutical Quality Assurance, online erschienen am 30.10.2026. Verfasst von Priyanka Choudhary und 2 weiteren Autor:innen.
Abstract (Originalsprache)
Background
Vitiligo is a chronic autoimmune disease due to loss of melanocytes. Patients experience anxiety, depression, and therefore higher morbidity. The goal of treatment for progressive vitiligo is to stop the disease's progression and help the afflicted lesions regain their color. The two mainstays of treatment are topical medications and NBUVB phototherapy. However, these treatments may not always be sufficient to halt the progression. Oral mini-pulse (OMP) steroid therapy is widely used to control disease activity; however, concerns regarding corticosteroid-related adverse effects have encouraged evaluation of more targeted treatments such as Tofacitinib.
Aim
To compare the effectiveness and safety of oral Tofacitinib 5mg twice daily versus oral mini-pulse (OMP) steroid therapy Betamethasone 0.1mg/kg/day in patients with progressive vitiligo.
Methods
This prospective, randomized, parallel-group, open-label blinded controlled study was conducted in the Department of Dermatology, KM Medical College, Mathura. Ninety-five patients with progressive vitiligo were randomly allocated to receive either oral Tofacitinib 5mg twice daily (group A) or oral mini-pulse steroid therapy Betamethasone 0.1 mg/kg/day on two consecutive days for 24 weeks (group B). Treatment efficacy was evaluated using the Vitiligo Area Scoring Index (VASI), disease stabilization, repigmentation, overall clinical response, and treatment-related adverse events. Participants were assessed at baseline and at weeks 4, 8, 12, 16, 20, and 24. Data were analyzed using SPSS version 26.0.
Results
Both treatment groups showed statistically significant clinical improvement. Oral Tofacitinib produced a greater reduction in VASI score, higher rates of disease stabilization and visible repigmentation, a better overall clinical response, and fewer treatment-related adverse events than oral mini-pulse steroid therapy. Pc added: Both groups improved significantly. Tofacitinib produced greater mean VASI reduction (3.24 ± 1.38 vs. 1.83 ± 1.19; p < 0.001), more visible repigmentation (70.8% vs. 46.8%; p = 0.017), and fewer adverse effects (22.9% vs. 42.6%, p = 0.041). Disease stabilization did not differ significantly (p = 0.114).
Conclusion
In this randomized study, tofacitinib was associated with greater improvement in VASI score and repigmentation outcomes compared with OMP therapy with fewer adverse events. Larger multicenter trials with extended follow-up are required to confirm these findings.
Zitieren
APA
Choudhary, P., Ghuman, R. K., & Moulidharan, B. (2026). A Comparative Analysis of Patients with Progressive Vitiligo Treated with Tofacitinib versus Oral Mini-Pulse Steroid Therapy. International Journal of Pharmaceutical Quality Assurance, 17(10). https://doi.org/10.25258/ijpqa.17.10.21
Vancouver
Choudhary P, Ghuman RK, Moulidharan B. A Comparative Analysis of Patients with Progressive Vitiligo Treated with Tofacitinib versus Oral Mini-Pulse Steroid Therapy. International Journal of Pharmaceutical Quality Assurance. 2026;17(10). doi:10.25258/ijpqa.17.10.21
BibTeX
@article{Choudhary2026,
author = {Choudhary, Priyanka and Ghuman, Rajinderjit Kaur and Moulidharan, Boddeda},
title = {A Comparative Analysis of Patients with Progressive Vitiligo Treated with Tofacitinib versus Oral Mini-Pulse Steroid Therapy},
journal = {International Journal of Pharmaceutical Quality Assurance},
year = {2026},
volume = {17},
number = {10},
doi = {10.25258/ijpqa.17.10.21}
}
EUVIMED